Temozolomide in children with progressive low-grade glioma

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mout...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gururangan, Sridharan, Fisher, Michael J., Allen, Jeffrey C., Herndon, James E., Quinn, Jennifer A., Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Phillips, Peter C., Watral, Melody A., Krauser, Jeanne M., Friedman, Allan H., Friedman, Henry S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Duke University Press 2007
Gaiak:
Special Focus: Pediatric Neuro-Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871667/
https://ncbi.nlm.nih.gov/pubmed/17347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-030
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak